Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Looking for a new opportunity in New Jersey? These nine companies have open roles that could be a great fit for you.

California-based clinical-stage biotech Juvena Therapeutics has entered a global licensing and multi-target research ...

However, considering it hovered near bear market territory a few weeks ago, things aren't so bad. Stocks might not be out of ...

The president wants a the most-favored-nation pricing model. But the U.S. drug industry is offering a host of reasons why ...

In a step forward for Australian dementia research, a new collaborative research project has been announced. America-based ...

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

Trans influencer Lilly Tino is facing intense backlash after posting a bathroom selfie from Disney World that showed other ...

The electronic health records market is experiencing robust growth, primarily driven by the increasing incidence of chronic diseases that require ong ...

Eli Lilly (NYSE:LLY) announced a significant global licensing and research collaboration with Juvena Therapeutics to explore ...